Evidence map›Paper›PMID 41524595›Full record

ArticleJournal of clinical microbiology2026

Tuberculosis diagnosis and the complete drug resistance pattern from a single sample within a single day by use of a composite platform of MAX MDR-TB and AmPORE-TB.

Harald Hoffmann, Andrey Golubov, Caroline Corbett, Dilfuza Allamuratova, Uladzimir Antonenka, Marion Heiß-Neumann, Sabine Hofmann-Thiel, Kripu Sharma, Laziz Turaev, Dzmitry Sinitski and 1 more

Abstract read
In one paragraph

Article in Journal of clinical microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Harald Hoffmann *Department IML red GmbH, WHO - Supranational Tuberculosis Reference Laboratory, Institute of Microbiology and Laboratory Medicine, Munich-Gauting, Bavaria, Germany.ORCID 0000-0003-4886-5022
Andrey Golubov *Department IML red GmbH, WHO - Supranational Tuberculosis Reference Laboratory, Institute of Microbiology and Laboratory Medicine, Munich-Gauting, Bavaria, Germany.
Caroline Corbett *Department IML red GmbH, WHO - Supranational Tuberculosis Reference Laboratory, Institute of Microbiology and Laboratory Medicine, Munich-Gauting, Bavaria, Germany.ORCID 0000-0001-7865-4563
Dilfuza AllamuratovaRepublican Specialized Scientific Practical Medical Centre of Phthisiology and Pulmonology under Ministry of Health of the Republic of Uzbekistan, Tashkent, Republic of Uzbekistan.
Uladzimir AntonenkaDepartment IML red GmbH, WHO - Supranational Tuberculosis Reference Laboratory, Institute of Microbiology and Laboratory Medicine, Munich-Gauting, Bavaria, Germany.
Marion Heiß-NeumannKuratorium Tuberkulose in der Welt e.V., Munich-Gauting, Bavaria, Germany.
Sabine Hofmann-ThielDepartment IML red GmbH, WHO - Supranational Tuberculosis Reference Laboratory, Institute of Microbiology and Laboratory Medicine, Munich-Gauting, Bavaria, Germany.
Kripu SharmaDepartment IML red GmbH, WHO - Supranational Tuberculosis Reference Laboratory, Institute of Microbiology and Laboratory Medicine, Munich-Gauting, Bavaria, Germany.
Laziz TuraevRepublican Specialized Scientific Practical Medical Centre of Phthisiology and Pulmonology under Ministry of Health of the Republic of Uzbekistan, Tashkent, Republic of Uzbekistan.
Dzmitry Sinitski *Department IML red GmbH, WHO - Supranational Tuberculosis Reference Laboratory, Institute of Microbiology and Laboratory Medicine, Munich-Gauting, Bavaria, Germany.
Olim Kabirov *National Reference Laboratory, Republican Tuberculosis Hospital Machiton, Vahdat city, Shifo, Republic of Tajikistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rapid TB diagnostics are essential for effective TB control. Combining WHO-recommended rapid molecular tests with downstream targeted next-generation sequencing (tNGS) enables faster drug resistance profiling. The objective of this study was to establish a one-day diagnostic platform (ODDP) integrating BD MAX MDR-TB and AmPORE-TB tNGS from a single sample. Pooled sputum samples spiked with 52 pre-characterized

Indexed as

Drug Resistance, BacterialDrug Resistance, Multiple, BacterialMolecular Diagnostic TechniquesMycobacterium tuberculosisTuberculosis, Multidrug-ResistantAntitubercular AgentsHigh-Throughput Nucleotide SequencingHumansMicrobial Sensitivity TestsRapid Diagnostic TestsSensitivity and SpecificitySputumTime FactorsAntitubercular AgentsAmPORE-TBBD Max MDR-TBdiagnosticsmWRDtargeted next-generation sequencingtuberculosis

Identifiers

PMID41524595
PMCPMC12892996

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.